Bristol-Myers Squibb Co (MIL:1BMY) ROE % Adjusted to Book Value: 9.12% (As of Mar. 2026)


MIL:1BMY Bristol-Myers Squibb Co MIL:1BMY
49 GF Score
Price €50.38
GF Value €47.53
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co ROE % Adjusted to Book Value?

Bristol-Myers Squibb Co MIL:1BMY 49 ROE % Adjusted to Book Value is 9.12% as of Mar. 2026. GuruFocus rates MIL:1BMY with a GF Score™ of 49/100 and a GF Value™ of €47.53 (Fairly Valued). The stock has 6 warning signs investors should review.

Bristol-Myers Squibb Co's ROE % for the quarter that ended in Mar. 2026 was 55.91%. Bristol-Myers Squibb Co's PB Ratio for the quarter that ended in Mar. 2026 was 6.13. Bristol-Myers Squibb Co's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 9.12%.


Bristol-Myers Squibb Co ROE % Adjusted to Book Value Related Terms


Bristol-Myers Squibb Co ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co ROE % Adjusted to Book Value Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 7.51 -5.56 6.48

Bristol-Myers Squibb Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 5.40 9.80 3.96 9.12

MIL:1BMY vs PFE, GILD, AMGN: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's ROE % Adjusted to Book Value falls into.


MIL:1BMY
49GF Score
Bristol-Myers Squibb Co MIL:1BMY
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co ROE % Adjusted to Book Value Calculation

Bristol-Myers Squibb Co's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=38.40% / 5.93
=6.48%

Bristol-Myers Squibb Co's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=55.91% / 6.13
=9.12%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 9.12% mean?
Bristol-Myers Squibb Co (MIL:1BMY) has a ROE % Adjusted to Book Value of 9.12% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's ROE % Adjusted to Book Value too high?
Bristol-Myers Squibb Co's current ROE % Adjusted to Book Value is 9.12%. Overall, Bristol-Myers Squibb Co has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's ROE % Adjusted to Book Value compare to PFE and GILD?
Bristol-Myers Squibb Co's ROE % Adjusted to Book Value of 9.12% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current ROE % Adjusted to Book Value is 9.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (MIL:1BMY) is currently considered Fairly Valued. The stock's GF Value™ is €47.53, compared to a current price of €50.38 — trading 6% above its estimated fair value. The current ROE % Adjusted to Book Value is 9.12%. Bristol-Myers Squibb Co's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Bristol-Myers Squibb Co (MIL:1BMY), the current ROE % Adjusted to Book Value is 9.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (MIL:1BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of €50.38 is trading 6% above its estimated GF Value™ of €47.53. GuruFocus considers Bristol-Myers Squibb Co to be Fairly Valued.

Key valuation signals for MIL:1BMY:

  • ROE % Adjusted to Book Value: 9.12%
  • GF Value™: €47.53 vs. price of €50.38 (6% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the MIL:1BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
49GF Score

Get the complete analysis for MIL:1BMY

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€50.38
Price
€47.53
GF Value